<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(9)</volume><submitter>Maranto C</submitter><pubmed_abstract>Androgen receptor (AR) drives prostate cancer (PC) growth and progression, and targeting AR signaling is the mainstay of pharmacological therapies for PC. Resistance develops relatively fast as a result of refueled AR activity. A major gap in the field is the lack of understanding of targetable mechanisms that induce persistent AR expression in castrate-resistant PC (CRPC). This study uncovers an unexpected function of active Stat5 signaling, a known promoter of PC growth and clinical progression, as a potent inducer of &lt;i>AR&lt;/i> gene transcription. Stat5 suppression inhibited &lt;i>AR&lt;/i> gene transcription in preclinical PC models and reduced the levels of wild-type, mutated, and truncated AR proteins. Pharmacological Stat5 inhibition by a specific small-molecule Stat5 inhibitor down-regulated Stat5-inducible genes as well as AR and AR-regulated genes and suppressed PC growth. This work introduces the concept of Stat5 as an inducer of &lt;i>AR&lt;/i> gene transcription in PC. Pharmacological Stat5 inhibitors may represent a new strategy for suppressing AR and CRPC growth.</pubmed_abstract><journal>Science advances</journal><pagination>eadi2742</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10901378</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Stat5 induces androgen receptor (&lt;i>AR&lt;/i>) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling.</pubmed_title><pmcid>PMC10901378</pmcid><pubmed_authors>Udhane V</pubmed_authors><pubmed_authors>McCluskey B</pubmed_authors><pubmed_authors>Johnson S</pubmed_authors><pubmed_authors>Qi S</pubmed_authors><pubmed_authors>Banerjee A</pubmed_authors><pubmed_authors>Sabharwal L</pubmed_authors><pubmed_authors>Wang L</pubmed_authors><pubmed_authors>Maranto C</pubmed_authors><pubmed_authors>Pitzen SP</pubmed_authors><pubmed_authors>Iczkowski KA</pubmed_authors><pubmed_authors>Nevalainen MT</pubmed_authors><pubmed_authors>Devi S</pubmed_authors><pubmed_authors>Dehm SM</pubmed_authors><pubmed_authors>O'Connor C</pubmed_authors><pubmed_authors>Jacobsohn K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Stat5 induces androgen receptor (&lt;i>AR&lt;/i>) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling.</name><description>Androgen receptor (AR) drives prostate cancer (PC) growth and progression, and targeting AR signaling is the mainstay of pharmacological therapies for PC. Resistance develops relatively fast as a result of refueled AR activity. A major gap in the field is the lack of understanding of targetable mechanisms that induce persistent AR expression in castrate-resistant PC (CRPC). This study uncovers an unexpected function of active Stat5 signaling, a known promoter of PC growth and clinical progression, as a potent inducer of &lt;i>AR&lt;/i> gene transcription. Stat5 suppression inhibited &lt;i>AR&lt;/i> gene transcription in preclinical PC models and reduced the levels of wild-type, mutated, and truncated AR proteins. Pharmacological Stat5 inhibition by a specific small-molecule Stat5 inhibitor down-regulated Stat5-inducible genes as well as AR and AR-regulated genes and suppressed PC growth. This work introduces the concept of Stat5 as an inducer of &lt;i>AR&lt;/i> gene transcription in PC. Pharmacological Stat5 inhibitors may represent a new strategy for suppressing AR and CRPC growth.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-22T06:39:45.073Z</modification><creation>2025-04-05T21:49:03.065Z</creation></dates><accession>S-EPMC10901378</accession><cross_references><pubmed>38416822</pubmed><doi>10.1126/sciadv.adi2742</doi></cross_references></HashMap>